“Speed to market is critical,” Organon believes, in the race to win share in the approaching biosimilar Humira (adalimumab) market, while price will move “pretty quickly” amid a “full out very competitive marketplace.”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?